{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T08:51:06Z","timestamp":1794473466764,"version":"4.9.1"},"reference-count":88,"publisher":"Elsevier BV","issue":"18","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,8,14]],"date-time":"2017-08-14T00:00:00Z","timestamp":1502668800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Spanish Ministry of Economy and Competiveness","award":["SAF2016-75638-R"],"award-info":[{"award-number":["SAF2016-75638-R"]}],"id":[{"id":"https:\/\/ror.org\/01txxn211","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100010801","name":"Xunta de Galicia","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100010801","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.bmcl.2017.08.027","type":"journal-article","created":{"date-parts":[[2017,8,14]],"date-time":"2017-08-14T19:00:18Z","timestamp":1502737218000},"page":"4221-4228","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":229,"title":["Antibiotic adjuvants \u2013 A strategy to unlock bacterial resistance to antibiotics"],"prefix":"10.1016","volume":"27","author":[{"given":"Concepci\u00f3n","family":"Gonz\u00e1lez-Bello","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmcl.2017.08.027_h0005","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/S1473-3099(13)70318-9","article-title":"Antibiotic resistance\u2014the need for global solutions","volume":"13","author":"Laxminarayan","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.bmcl.2017.08.027_h0010","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1038\/nrd940","article-title":"The future challenges facing the development of new antimicrobial drugs","volume":"1","author":"Coates","year":"2002","journal-title":"Nat Rev Drug Discovery"},{"key":"10.1016\/j.bmcl.2017.08.027_h0015","unstructured":"(a) European centre for disease prevention and control (ECDC). The bacterial challenge: time to react. http:\/\/ecdc.europa.eu\/en\/publications\/Publications\/0909_TER_The_Bacterial_Challenge_Time_to_React.pdf."},{"key":"10.1016\/j.bmcl.2017.08.027_h0020","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1086\/375081","article-title":"The impact of antimicrobial resistance on health and economic outcomes","volume":"36","author":"Cosgrove","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.bmcl.2017.08.027_h0025","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1086\/605631","article-title":"Antibiotic resistance: who will pay the bills?","volume":"49","author":"Zaoutis","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.bmcl.2017.08.027_b0015","unstructured":"WHO (2017) Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. http:\/\/www.who.int\/medicines\/publications\/WHO-PPL-Short_Summary_25Feb-ET_NM_WHO.pdf?ua=1. February 27, 2017."},{"key":"10.1016\/j.bmcl.2017.08.027_b0020","doi-asserted-by":"crossref","first-page":"4943","DOI":"10.1128\/AAC.00296-11","article-title":"Carbapenems: past, present, and future","volume":"55","author":"Papp-Wallace","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmcl.2017.08.027_b0025","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1038\/nature17042","article-title":"Antibacterial drug discovery in the resistance era","volume":"529","author":"Brown","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.bmcl.2017.08.027_b0030","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/nature10388","article-title":"Antibiotic resistance is ancient","volume":"477","author":"D\u2019Costa","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.bmcl.2017.08.027_h0050","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1126\/science.aaj2191","article-title":"Antibiotic tolerance facilitates the evolution of resistance","volume":"355","author":"Levin-Reisman","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.bmcl.2017.08.027_h0055","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1177\/2042098614554919","article-title":"Antimicrobial resistance: risk associated with antibiotic overuse and initiatives to reduce the problem","volume":"5","author":"Llor","year":"2014","journal-title":"Ther Adv Drug Saf"},{"key":"10.1016\/j.bmcl.2017.08.027_h0060","doi-asserted-by":"crossref","first-page":"E2498","DOI":"10.1073\/pnas.1601208113","article-title":"Antibiotic treatment enhances the genome-wide mutation rate of target cells","volume":"113","author":"Long","year":"2016","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bmcl.2017.08.027_h0065","doi-asserted-by":"crossref","first-page":"20140086","DOI":"10.1098\/rstb.2014.0086","article-title":"Time for a change: addressing R&D and commercialization challenges for antibacterials","volume":"370","author":"Payne","year":"2015","journal-title":"Philos Trans R Soc B"},{"key":"10.1016\/j.bmcl.2017.08.027_h0070","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/bcp.12401","article-title":"Meeting the societal need for new antibiotics: the challenges for the pharmaceutical industry","volume":"79","author":"O\u2019Brien","year":"2015","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.bmcl.2017.08.027_h0075","first-page":"36","article-title":"Antibiotics: will the bugs always win?","volume":"94","author":"Thayer","year":"2016","journal-title":"Chem Eng News"},{"key":"10.1016\/j.bmcl.2017.08.027_h0080","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/S1473-3099(15)00500-9","article-title":"Antibiotic reimbursement in a model delinked from sales a benchmark-based worldwide approach","volume":"16","author":"Rex","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.bmcl.2017.08.027_h0085","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.coph.2015.06.003","article-title":"The global challenge of new classes of antibacterial agents: an industry perspective","volume":"24","author":"Fernandes","year":"2015","journal-title":"Curr Opin Pharm"},{"key":"10.1016\/j.bmcl.2017.08.027_h0090","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/anie.201506818","article-title":"Targeting antibiotic resistance","volume":"55","author":"Chellat","year":"2016","journal-title":"Angew Chem Int Ed"},{"key":"10.1016\/j.bmcl.2017.08.027_h0095","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/nrd3975","article-title":"Platforms for antibiotic discovery","volume":"12","author":"Lewis","year":"2013","journal-title":"Nat Rev Drug Dis"},{"key":"10.1016\/j.bmcl.2017.08.027_h0100","unstructured":"(a) Data from the PEW charitable trusts, December 2016. http:\/\/www.pewtrusts.org\/~\/media\/assets\/2016\/12\/antibiotics_datatable_201612.pdf."},{"key":"10.1016\/j.bmcl.2017.08.027_h0105","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.bcp.2016.09.025","article-title":"Antibiotics in late clinical development","volume":"133","author":"Fernandes","year":"2017","journal-title":"Biochem Pharm"},{"key":"10.1016\/j.bmcl.2017.08.027_h0110","first-page":"9","article-title":"Insights into newer antimicrobial agents against Gram-negative bacteria","volume":"9","author":"Taneja","year":"2016","journal-title":"Microb Insights"},{"key":"10.1016\/j.bmcl.2017.08.027_h0115","unstructured":"(a) http:\/\/www.carb-x.org\/."},{"key":"10.1016\/j.bmcl.2017.08.027_h0120","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1093\/jac\/dkv339","article-title":"The innovative medicines initiative\u2019s new drugs for bad bugs programme: European public-private partnerships for the development of new strategies to tackle antibiotic resistance","volume":"71","author":"Kostyanev","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.bmcl.2017.08.027_b0060","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1038\/nm1116-1197","article-title":"What\u2019s old is new: reconfiguring known antibiotics to fight drug resistance","volume":"22","author":"Chakradhar","year":"2016","journal-title":"Nat Med"},{"key":"10.1016\/j.bmcl.2017.08.027_b0065","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/cbdd.12478","article-title":"Antibiotic adjuvants: diverse strategies for controlling drug-resistant pathogens","volume":"85","author":"Gill","year":"2015","journal-title":"Chem Biol Drug Des"},{"key":"10.1016\/j.bmcl.2017.08.027_b0070","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1111\/1751-7915.12044","article-title":"Antibiotic adjuvants: identification and clinical use","volume":"6","author":"Bernal","year":"2013","journal-title":"Microb Biotechnol"},{"key":"10.1016\/j.bmcl.2017.08.027_b0075","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.1017\/S1462399410001766","article-title":"Antibiotic adjuvants: multicomponent anti-infective strategies","volume":"13","author":"Kalan","year":"2011","journal-title":"Expert Rev Mol Med"},{"key":"10.1016\/j.bmcl.2017.08.027_b0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/nbt.2500","article-title":"Discovery of antibiotic adjuvants","volume":"31","author":"Farha","year":"2013","journal-title":"Nat Biotech"},{"key":"10.1016\/j.bmcl.2017.08.027_b0085","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1038\/nrd4675","article-title":"Antibiotic resistance breakers: can repurposed drugs fill the antibiotic discovery void?","volume":"14","author":"Brown","year":"2015","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.bmcl.2017.08.027_b0090","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.tibtech.2012.12.006","article-title":"Combination approaches to combat multidrug-resistant bacteria","volume":"31","author":"Worthington","year":"2013","journal-title":"Trends Biotechnol"},{"key":"10.1016\/j.bmcl.2017.08.027_b0095","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1021\/acsinfecdis.5b00100","article-title":"Investigational agents for the treatment of Gram-negative bacterial infections: a reality check","volume":"13","author":"Bush","year":"2015","journal-title":"ACS Infect Dis"},{"key":"10.1016\/j.bmcl.2017.08.027_b0100","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.tim.2016.06.009","article-title":"Antibiotic adjuvants: rescuing antibiotics from resistance","volume":"24","author":"Wright","year":"2016","journal-title":"Trends Microb"},{"key":"10.1016\/j.bmcl.2017.08.027_b0105","doi-asserted-by":"crossref","DOI":"10.1021\/acsinfecdis.7b00071","article-title":"The challenge of overcoming antibiotic resistance: an adjuvant approach?","author":"Melander","year":"2017","journal-title":"ACS Infect Dis"},{"key":"10.1016\/j.bmcl.2017.08.027_h0175","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/35021219","article-title":"Molecular mechanisms that confer antibacterial drug resistance","volume":"406","author":"Walsh","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.bmcl.2017.08.027_h0180","first-page":"42","article-title":"Molecular mechanisms of antibiotic resistance","volume":"13","author":"Blair","year":"2015","journal-title":"Nat Rev"},{"key":"10.1016\/j.bmcl.2017.08.027_h0185","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/nchembio.2007.24","article-title":"Targeting virulence: a new paradigm for antimicrobial therapy","volume":"3","author":"Clatworthy","year":"2007","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.bmcl.2017.08.027_h0190","first-page":"117","article-title":"Anti-virulence strategies to combat bacteria-mediated disease","volume":"9","author":"Rasko","year":"2010","journal-title":"Nat Rev"},{"key":"10.1016\/j.bmcl.2017.08.027_h0195","doi-asserted-by":"crossref","first-page":"4422","DOI":"10.1021\/acs.chemrev.6b00676","article-title":"Chemical strategies to target bacterial virulence","volume":"117","author":"Garland","year":"2017","journal-title":"Chem Rev"},{"key":"10.1016\/j.bmcl.2017.08.027_h0200","doi-asserted-by":"crossref","first-page":"9162","DOI":"10.1021\/acs.chemrev.6b00184","article-title":"Plant natural products targeting bacterial virulence factors","volume":"116","author":"Silva","year":"2016","journal-title":"Chem Rev"},{"key":"10.1016\/j.bmcl.2017.08.027_b0125","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1128\/AAC.00826-13","article-title":"New \u03b2-lactamase inhibitors: a therapeutic renaissance in an MDR world","volume":"58","author":"Drawz","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmcl.2017.08.027_h0210","unstructured":"(a) Data from https:\/\/www.ncbi.nlm.nih.gov\/pathogens\/beta-lactamase-data-resources\/, accessed May 2017."},{"key":"10.1016\/j.bmcl.2017.08.027_h0215","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1021\/ar300327a","article-title":"Class D \u03b2-lactamases: a reappraisal after five decades","volume":"46","author":"Leonard","year":"2013","journal-title":"Acc Chem Res"},{"key":"10.1016\/j.bmcl.2017.08.027_b0135","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.jmb.2010.12.042","article-title":"Structures of the class D carbapenemase OXA-24 from Acinetobacter baumannii in complex with doripenem","volume":"406","author":"Schneider","year":"2011","journal-title":"J Mol Biol"},{"key":"10.1016\/j.bmcl.2017.08.027_b0140","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1128\/AAC.11.5.852","article-title":"Clavulanic acid: a beta-lactamase-inhibiting beta-Lactam from Streptomyces clavuligerus","volume":"11","author":"Reading","year":"1977","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmcl.2017.08.027_b0145","doi-asserted-by":"crossref","first-page":"3449","DOI":"10.1016\/S0040-4039(00)84819-4","article-title":"Synthesis of a potent \u03b2-lactamase","volume":"27","author":"Chen","year":"1986","journal-title":"Tetrahedron Lett"},{"key":"10.1016\/j.bmcl.2017.08.027_b0150","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1128\/AAC.33.9.1580","article-title":"In vitro evaluation of BRL 42715, a Novel \u03b2-lactamase inhibitor","volume":"33","author":"Coleman","year":"1989","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmcl.2017.08.027_b0155","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1074\/jbc.M806833200","article-title":"Strategic design of an effective \u03b2-lactamase inhibitor","volume":"284","author":"Pattanalk","year":"2009","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bmcl.2017.08.027_b0160","doi-asserted-by":"crossref","first-page":"13320","DOI":"10.1021\/ja104092z","article-title":"Design, synthesis, and crystal structures of 6-alkylidene-2'-substituted penicillanic acid sulfones as potent inhibitors of Acinetobacter baumannii OXA-24 carbapenemase","volume":"132","author":"Bou","year":"2010","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.bmcl.2017.08.027_b0165","doi-asserted-by":"crossref","DOI":"10.1021\/acs.jmedchem.7b00554","article-title":"Bacterial iron uptake pathways: gates for the import of bactericide compounds","author":"Schalk","year":"2017","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2017.08.027_h0255","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1093\/jac\/dkw105","article-title":"LN-1-255, a penicillanic acid sulfone able to inhibit the class D carbapemenease OXA-48","volume":"7","author":"Vallejo","year":"2016","journal-title":"J Antim Chemother"},{"key":"10.1016\/j.bmcl.2017.08.027_h0260","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01172-17","article-title":"Activity of the \u03b2-lactamase inhibitor LN-1-255 against carbapenem-hydrolyzing class D \u03b2-lactamases from Acinetobacter baumannii","author":"V\u00e1zquez-Ucha","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmcl.2017.08.027_b0175","doi-asserted-by":"crossref","first-page":"11663","DOI":"10.1073\/pnas.1205073109","article-title":"Avibactam is a covalent, reversible, non-\u03b2-lactam \u03b2-lactamase inhibitor","volume":"109","author":"Ehmann","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bmcl.2017.08.027_b0180","doi-asserted-by":"crossref","first-page":"4848","DOI":"10.1128\/AAC.00762-13","article-title":"Structures of the class D carbapenemases OXA-23 and OXA-146: mechanistic basis of activity against carbapenems, extended-spectrum cephalosporins, and aztreonam","volume":"57","author":"Kaitany","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmcl.2017.08.027_b0185","doi-asserted-by":"crossref","first-page":"e01636","DOI":"10.1128\/AAC.01636-16","article-title":"Active-site protonation states in an acyl-enzyme intermediate of a class A beta-lactamase with a monobactam substrate","volume":"61","author":"Vandavasi","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmcl.2017.08.027_b0190","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2147\/CE.S40698","article-title":"Ceftazidime\u2013avibactam: an evidence-based review of its pharmacology and potential use in the treatment of Gram-negative bacterial infections","volume":"9","author":"Lagac\u00e9-Wiens","year":"2014","journal-title":"Core Evid"},{"key":"10.1016\/j.bmcl.2017.08.027_h0285","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1021\/acschembio.5b00944","article-title":"Structural and kinetic characterization of diazabicyclooctanes as dual inhibitors of both serine-\u03b2-lactamases and penicillin binding proteins","volume":"11","author":"King","year":"2016","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.bmcl.2017.08.027_h0290","doi-asserted-by":"crossref","first-page":"27960","DOI":"10.1074\/jbc.M113.485979","article-title":"Kinetics of avibactam inhibition against class A, C, and D \u03b2-lactamases","volume":"288","author":"Ehmann","year":"2013","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bmcl.2017.08.027_b0200","doi-asserted-by":"crossref","first-page":"17104","DOI":"10.1038\/nmicrobiol.2017.104","article-title":"ETX2514 is a broad-spectrum \u03b2-lactamase inhibitor for the treatment of drug-resistant Gram-negative bacteria including Acinetobacter baumannii","volume":"2","author":"Durand-R\u00e9ville","year":"2017","journal-title":"Nat Microb"},{"key":"10.1016\/j.bmcl.2017.08.027_b0205","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1021\/cb500703p","article-title":"Molecular basis of selective inhibition and slow reversibility of avibactam against class D carbapenemases: a structure-guided study of OXA-24 and OXA-48","volume":"10","author":"Lahiri","year":"2015","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.bmcl.2017.08.027_b0210","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1021\/acsinfecdis.5b00007","article-title":"Molecular mechanism of avibactam-mediated \u03b2-lactamase inhibition","volume":"1","author":"King","year":"2015","journal-title":"ACS Infect Dis"},{"key":"10.1016\/j.bmcl.2017.08.027_b0215","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1093\/jac\/dkv166","article-title":"OP0595, a new diazabicyclooctane: mode of action as a serine \u03b2-lactamase inhibitor, antibiotic and \u03b2-lactam \u201cenhancer\u201d","volume":"70","author":"Morinaka","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.bmcl.2017.08.027_b0220","doi-asserted-by":"crossref","first-page":"4156","DOI":"10.1021\/cr608202m","article-title":"Boron containing compounds as protease inhibitors","volume":"112","author":"Smoum","year":"2012","journal-title":"Chem Rev"},{"key":"10.1016\/j.bmcl.2017.08.027_b0225","first-page":"4","article-title":"Reversible inhibitors of penicillinases","volume":"169","author":"Kiener","year":"1978","journal-title":"Biochem J"},{"key":"10.1016\/j.bmcl.2017.08.027_b0230","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1042\/bj2090229","article-title":"The inhibition of class C \u03b2-lactamases by boronic acids","volume":"209","author":"Beesley","year":"1983","journal-title":"Biochem J"},{"key":"10.1016\/j.bmcl.2017.08.027_h0330","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/j.bmc.2007.10.075","article-title":"Structure-based optimization of cephalothin-analogue boronic acids as \u03b2-lactamase inhibitors","volume":"16","author":"Morandi","year":"2008","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmcl.2017.08.027_h0335","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1021\/ja0288338","article-title":"PratiF. Nanomolar inhibitors of AmpC beta-lactamase","volume":"22","author":"Morandi","year":"2003","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.bmcl.2017.08.027_b0240","doi-asserted-by":"crossref","first-page":"17448","DOI":"10.1073\/pnas.1208337109","article-title":"Fragment-guided design of subnanomolar \u03b2-lactamase inhibitors active in vivo","volume":"109","author":"Eidama","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bmcl.2017.08.027_b0245","doi-asserted-by":"crossref","first-page":"3682","DOI":"10.1021\/acs.jmedchem.5b00127","article-title":"Discovery of a cyclic boronic acid \u03b2-lactamase inhibitor (RPX7009) with utility vs class A serine carbapenemases","volume":"58","author":"Hecker","year":"2015","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2017.08.027_h0350","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1128\/AAC.02418-12","article-title":"In vitro activity of biapenem plus RPX7009, a carbapenem combined with a serine-lactamase inhibitor, against anaerobic bacteria","volume":"57","author":"Goldstein","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmcl.2017.08.027_h0355","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S1074-5521(00)00052-1","article-title":"Energetic, structural, and antimicrobial analyses of \u03b2-lactam side chain recognition by \u03b2-lactamases","volume":"8","author":"Caselli","year":"2001","journal-title":"Chem Biol"},{"key":"10.1016\/j.bmcl.2017.08.027_b0255","doi-asserted-by":"crossref","first-page":"3974","DOI":"10.1073\/pnas.77.7.3974","article-title":"Active efflux of tetracycline encoded by four genetically different tetracycline resistance determinants in Escherichia coli","volume":"77","author":"McMurry","year":"1980","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bmcl.2017.08.027_b0260","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1016\/j.addr.2005.04.004","article-title":"Bacterial resistance to antibiotics: active efflux and reduced uptake","volume":"57","author":"Kumar","year":"2005","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.bmcl.2017.08.027_b0265","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.2174\/138161211795703726","article-title":"Microbial efflux pump inhibition: tactics and strategies","volume":"17","author":"Tegos","year":"2011","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.bmcl.2017.08.027_b0270","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/nrmicro1464","article-title":"Multidrug-resistance efflux pumps - not just for resistance","volume":"20","author":"Piddock","year":"2006","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.bmcl.2017.08.027_b0275","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1128\/CMR.19.2.382-402.2006","article-title":"Clinically relevant chromosomally encoded multidrug resistance efflux pumps in bacteria","volume":"19","author":"Piddock","year":"2006","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.bmcl.2017.08.027_b0280","first-page":"138","article-title":"Inhibitors of bacterial efflux pumps as adjuvants in antibacterial therapy and diagnostic tools for detection of resistance by efflux","volume":"1","author":"van Bambeke","year":"2010","journal-title":"Front Anti-Infect Drug Discov"},{"key":"10.1016\/j.bmcl.2017.08.027_b0285","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2174\/157489109787236256","article-title":"Inhibitors of multidrug resistant efflux systems in bacteria","volume":"4","author":"Zechini","year":"2009","journal-title":"Recent Pat Anti-Infect Drug Discovery"},{"key":"10.1016\/j.bmcl.2017.08.027_b0290","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1517\/17460441.2012.688949","article-title":"Understanding efflux in Gram-negative bacteria: opportunities for drug discovery","volume":"7","author":"Schweizer","year":"2012","journal-title":"Expert Opin Drug Discov"},{"key":"10.1016\/j.bmcl.2017.08.027_b0295","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1021\/acsinfecdis.6b00167","article-title":"Reviving antibiotics: efflux pump inhibitors that interact with AcrA, a membrane fusion protein of the AcrAB-TolC multidrug efflux pump","volume":"3","author":"Abdali","year":"2017","journal-title":"ACS Infect Dis"},{"key":"10.1016\/j.bmcl.2017.08.027_h0405","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.2174\/0929867323666160304150522","article-title":"Current advances in developing inhibitors of bacterial multidrug efflux pumps","volume":"23","author":"Mahmood","year":"2016","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.bmcl.2017.08.027_h0410","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1093\/jac\/dkl493","article-title":"Antibiotic efflux pumps in Gram-negative bacteria: the inhibitor response strategy","volume":"59","author":"Mahamoud","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.bmcl.2017.08.027_h0415","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1021\/ja982938m","article-title":"Incremental conversion of outer-membrane permeabilizers into potent antibiotics for Gram-negative bacteria","volume":"121","author":"Li","year":"1999","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.bmcl.2017.08.027_h0420","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1128\/AAC.50.5.1623-1627.2006","article-title":"Polyamines increase antibiotic susceptibility in Pseudomonas aeruginosa","volume":"50","author":"Kwon","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmcl.2017.08.027_b0310","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1128\/AAC.45.1.105-116.2001","article-title":"Identification and characterization of inhibitors of multidrug resistance efflux pumps in Pseudomonas aeruginosa: novel agents for combination therapy","volume":"45","author":"Lomovskaya","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmcl.2017.08.027_b0315","doi-asserted-by":"crossref","first-page":"e18547","DOI":"10.1371\/journal.pone.0018547","article-title":"Evaluation of multidrug efflux pump inhibitors by a new method using microfluidic channels","volume":"6","author":"Matsumoto","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.bmcl.2017.08.027_b0320","doi-asserted-by":"crossref","first-page":"e60666","DOI":"10.1371\/journal.pone.0060666","article-title":"The efflux inhibitor phenylalanine-arginine beta-naphthylamide (PA\u03b2N) permeabilizes the outer membrane of gram-negative bacteria","volume":"8","author":"Lamers","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.bmcl.2017.08.027_b0325","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/j.1749-6632.2012.06796.x","article-title":"Metallo-\u03b2-lactamase structure and function","volume":"1277","author":"Palzkill","year":"2013","journal-title":"Ann N Y Acad Sci"}],"container-title":["Bioorganic & Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X17308284?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X17308284?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T07:17:52Z","timestamp":1760771872000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X17308284"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":88,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["S0960894X17308284"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2017.08.027","relation":{},"ISSN":["0960-894X"],"issn-type":[{"value":"0960-894X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antibiotic adjuvants \u2013 A strategy to unlock bacterial resistance to antibiotics","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2017.08.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}